An exploratory analysis of the cost‐effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model

Hui Shao,Lizheng Shi,Vivian Fonseca,Abdul Jabbar Omar Alsaleh,Jasvinder Gill,Charlie Nicholls
DOI: https://doi.org/10.1111/dme.15303
IF: 3.5
2024-03-13
Diabetic Medicine
Abstract:Background This analysis assessed the cost‐effectiveness of insulin glargine 300 units/mL (Gla‐300) versus insulin glargine 100 units/mL (Gla‐100) in insulin‐naïve adults with type 2 diabetes (T2D) inadequately controlled with oral antidiabetic drugs (OADs). Methods Costs and outcomes for Gla‐300 versus Gla‐100 from a US healthcare payer perspective were assessed using the BRAVO diabetes model. Baseline clinical data were derived from EDITION‐3, a 12‐month randomized controlled trial comparing Gla‐300 with Gla‐100 in insulin‐naïve adults with inadequately controlled T2D on OADs. Treatment costs were calculated based on doses observed in EDITION‐3 and 2020 US net prices, while costs for complications were based on published literature. Lifetime costs ( ‐ ‐ ‐ 353,441 and ‐ ‐ 52,613 and ‐ ‐ ‐ ‐ 7522/QALY gained for Gla‐300 versus Gla‐100. Thus, Gla‐300 was cost‐effective versus Gla‐100 based on a willingness‐to‐pay threshold of ‐ ‐ 3290. Scenario and sensitivity analyses confirmed the robustness of the base case. Conclusion Gla‐300 may be a cost‐effective treatment option versus Gla‐100 over a lifetime horizon for insulin‐naïve people in the United States with T2D inadequately controlled on OADs.
endocrinology & metabolism
What problem does this paper attempt to address?